Lipella Pharmaceuticals Inc. (OTCPK: LIPO)
Health Care · Biotechnology · US
$0.00
+100.00% today · -99.9% 1Y
Lipella Pharmaceuticals Inc. (OTCPK: LIPO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.85K and employs 7 people.
Over the last twelve months the share price has lost 99.9%, trading between 0.00 and 0.64.
Tweenvest scores Lipella Pharmaceuticals Inc. across four factors: quality 31/100, value 43/100, growth 85/100. Its strongest factor is growth.
LIPO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.85K
- Revenue (TTM)
- $389.78K
- P/E
- —
- EPS
- -1.76
- Dividend yield
- —
- Beta (5Y)
- 1.56
- 52-week high
- $0.64
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 4.62M
- Employees
- 7
- Next earnings
- —
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
- Founded
- 2005
- Listed since
- Dec 19, 2022
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.31 | +0.51% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.